XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue:    
Total revenue $ 60,827 $ 38,429
Operating costs and expenses:    
Cost of goods sold $ 4,238 $ 3,401
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 89,018 $ 74,676
Selling, general and administrative 30,564 30,779
Total operating costs and expenses 123,820 108,856
Loss from operations (62,993) (70,427)
Interest and other, net    
Interest expense (97) (501)
Interest income and other income (expenses), net (322) (453)
Total interest and other, net (419) (954)
Loss before income taxes (63,412) (71,381)
Provision for income taxes 113 134
Investment income (loss) in unconsolidated variable interest entity 320 (240)
Net loss $ (63,205) $ (71,755)
Net loss per share - basic and diluted $ (0.68) $ (0.78)
Weighted average number of common shares used to calculate net loss per share - basic and diluted 93,043 91,688
License Revenue [Member]    
Revenue:    
Total revenue $ 22,590 $ 0
Development and Other Revenue [Member]    
Revenue:    
Total revenue 11,762 14,587
Product Revenue, Net [Member]    
Revenue:    
Total revenue 18,881 15,362
Drug Product Revenue [Member]    
Revenue:    
Total revenue $ 7,594 $ 8,480